Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the …
Biotechnology
US, Cambridge [HQ]
Ratios
9 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross Margin | 100.00 | 100.00 | 100.00 | 100.00 | -151.52 | -159.35 | 79.15 | 85.47 | 75.26 | |
| Profit Margin | -205.11 | -191.97 | -258.62 | -280.42 | -215.06 | -216.52 | -785.76 | -940.52 | -1,326.51 | |
| Operating Margin | -221.86 | -195.15 | -266.32 | -298.58 | -246.78 | -235.51 | -810.37 | -879.04 | -1,420.51 | |
|
EPS Growth
|
- - | -102.86 | -32.39 | -5.32 | 1.01 | -14.29 | -63.39 | -74.04 | 14.91 | |
| EPS USD | -70.00 | -142.00 | -188.00 | -198.00 | -196.00 | -224.00 | -366.00 | -637.00 | -542.00 | |
| Return on Assets (ROA) | -15.09 | -10.58 | -17.95 | -24.57 | -27.73 | -18.57 | -20.06 | -32.25 | -36.99 | |
| Return on Equity (ROE) | -18.41 | -15.08 | -22.47 | -30.71 | -34.35 | -23.82 | -24.97 | -39.67 | -45.82 | |
| Return on Invested Capital (ROIC) | -18.41 | -14.79 | -22.11 | -34.81 | -34.37 | -22.56 | -23.30 | -34.67 | -39.64 | |
| Solvency | ||||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | - - | - - | - - | - - | 5.50 | 5.81 | 5.72 | 8.60 | 8.87 | |
| Debt/Equity | - - | - - | - - | - - | 6.81 | 7.46 | 7.12 | 10.58 | 10.98 | |
| Debt/EBITDA | 579.59 | 849.11 | 489.80 | 64.77 | 38.55 | 88.38 | 18.44 | 88.33 | 22.01 | |
|
Debt/Capitalization
|
- - | - - | - - | - - | 6.37 | 6.94 | 6.64 | 9.57 | 9.90 | |
| Long-Term Debt/Capitalization | - - | - - | - - | - - | 4.47 | 5.99 | 5.87 | 8.45 | 8.44 | |
| Interest Debt per Share USD | - - | - - | - - | - - | 0.39 | 0.70 | 1.04 | 1.81 | 1.30 | |
| Debt Growth | - - | - - | - - | - - | - - | 113.91 | 88.33 | 76.57 | -11.75 | |
| Liquidity | ||||||||||
| Current Ratio | 725.82 | 915.41 | 1,131.51 | 800.99 | 812.40 | 929.70 | 611.37 | 961.48 | 866.55 | |
| Quick Ratio | 718.24 | 909.59 | 1,119.77 | 792.68 | 797.99 | 933.02 | 596.60 | 945.36 | 823.45 | |
| Cash Ratio | 708.89 | 888.59 | 1,086.38 | 145.07 | 160.60 | 249.04 | 98.07 | 413.66 | 196.82 | |
| Operating Cash Flow Ratio | - - | 100 | -200 | -100 | -200 | - - | -100 | -200 | -300 | |
| Turnover | ||||||||||
| Inventory Turnover | - - | - - | - - | - - | - - | -785.58 | -2.04 | -10.92 | - - | |
| Receivables Turnover | 604.40 | 255.33 | 249.42 | 403.26 | 932.97 | 2,722.72 | 1,627.43 | 1,383.25 | 99.50 | |
| Payables Turnover | - - | - - | - - | - - | 2,750.90 | 1,437.94 | 71.39 | 146.92 | 120.45 | |
|
Asset Turnover
|
7.36 | 5.51 | 6.94 | 8.76 | 12.89 | 8.57 | 2.55 | 3.43 | 2.79 | |
| Fixed Turnover | 223.19 | 155.05 | 171.01 | 178.38 | 116.08 | 105.33 | 33.02 | 32.37 | 24.49 | |
| Coverage | ||||||||||
| Interest Coverage | - - | - - | - - | - - | - - | - - | - - | -5,363.66 | - - | |
| Asset Coverage | - - | - - | - - | - - | 1,600 | 1,500 | 1,500 | 1,000 | 1,000 | |
| Cash Flow Coverage (CFGR) | - - | - - | - - | - - | -561.85 | -126.99 | -304.00 | -255.00 | -341.66 | |
| EBITDA Coverage | - - | - - | - - | - - | - - | - - | - - | -5,200 | - - | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -3.18 | -10.86 | -9.76 | -14.52 | -13.37 | -4.12 | -3.10 | -18.25 | -17.78 | |
|
Price/Earnings (P/E)
|
-3,148.94 | -920.94 | -1,024.58 | -688.86 | -747.71 | -2,425.53 | -3,227.54 | -547.84 | -562.48 | |
| Price/Earnings Growth (PEG) | - - | -8.95 | -31.63 | -129.51 | 740.23 | -169.79 | -50.91 | -7.40 | 37.72 | |
|
Price/Book (P/B)
|
579.57 | 138.84 | 230.22 | 211.53 | 256.82 | 577.85 | 805.82 | 217.35 | 257.73 | |
| Price/Tangible Book (P/TB) | 579.57 | 138.84 | 230.22 | 211.53 | 256.82 | 577.85 | 805.82 | 217.35 | 257.73 | |
| Price/Sales (P/S) | 6,458.87 | 1,767.89 | 2,649.75 | 1,931.69 | 1,608.04 | 5,251.74 | 25,360.80 | 5,152.54 | 7,461.33 | |
|
Price/Cash Flow (P/CF)
|
-22,142.62 | 806.81 | -1,060.17 | -959.71 | -671.36 | -6,102.13 | -3,725.06 | -805.78 | -686.80 | |
| Price/Free CF (P/FCF) | -9,042.72 | 972.92 | -918.22 | -869.47 | -629.91 | -5,693.20 | -3,525.23 | -685.66 | -663.27 | |
| Price/Operating CF (P/OCF) | -22,142.62 | 806.81 | -1,060.17 | -959.71 | -671.36 | -6,102.13 | -3,725.06 | -805.78 | -686.80 |